IP Library Granted Patent US 9,562,874
Granted Patent B2
US 9,562,874 · App. 14/206,174 · Granted Feb 7, 2017

Biosensor with improved interference characteristics

Inventors: Glenn Martin (Ottawa, CA); G. Bruce Collier (Fitzroy Harbour, CA); Dan Wang (Kanata, CA)
Assignee: Abbott Point of Care Inc.
G01N27/3271C12Q1/004G01N27/3277G01N2333/90206G01N2333/90683
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,562,874
App. No.
14/206,174
Granted
Feb 7, 2017
Kind
B2
Abstract

This invention relates to mutagenized redox oxidase enzymes used to design enzyme electrodes with improved interference characteristics in the presence of mediator and oxygen in the assay. This recombinant modified enzyme has enhanced capability to transfer electrons to redox mediator instead of its natural electron acceptors such as O 2 , NAD, NADP, etc., which will improve the assay performance with less interference and higher sensitivity.

Claims (34)

1. A device for detecting a target analyte, the device comprising:

an electrochemical cell;

an electron redox mediating molecule; and

a recombinant modified enzyme engineered to:

prevent transfer of electrons to a natural electron acceptor;

transfer electrons to the electron redox mediating molecule; and

provide enzymatic activity against the target analyte to generate an electrochemical signal dependent on a concentration of the target analyte in a sample.

2. The device of claim 1 , wherein the natural electron acceptor is oxygen, nicotinamide adenine dinucleotide (NAD), or nicotinamide adenine dinucleotide phosphate (NADP).

3. The device of claim 2 , wherein the sample comprises oxygen, NAD, or NADP.

4. The device of claim 1 , wherein the detecting the target analyte does not require removal of oxygen from the sample.

5. The device of claim 1 , wherein the target analyte is selected from the group consisting of sarcosine, glucose, lactose, creatinine, creatine, pyruvate, and bilirubin.

6. The device of claim 1 , wherein the electron redox mediating molecule is selected from the group consisting of: ferrocene, ferrocene derivatives, ferrocyanide, quinone derivatives, osmium complexes, ruthenium complexes, transition metal complexes, iron organo complexes, polypyrrole and other conductive polymers, tetracyanoquinodimethane (TCNQ), and methylene blue and other organic dyes.

7. The device of claim 1 , wherein the recombinant modified enzyme comprises a mutation of a protein coding sequence for a starting enzyme.

8. The device of claim 7 , wherein the starting enzyme is selected from the group consisting of: an oxidoreductase, a transferase, a hydrolase, and a lyase.

9. The device of claim 7 , wherein the recombinant modified enzyme is an oxidase with an inability to transfer electrons to oxygen.

10. The device of claim 7 , wherein the starting enzyme is sarcosine oxidase and the mutation is a Lys265 to Arg265 mutation of the starting enzyme.

11. The device of claim 7 , wherein the starting enzyme is a wild-type sarcosine oxidase produced by genus Bacillus.

12. The device of claim 7 , wherein the protein coding structure is for sp-p40859 from Bacillus spp. Strain B-0618.

13. The device of claim 7 , wherein the starting enzyme is sarcosine oxidase and the mutation is at a target site of the starting enzyme selected from the group consisting of: Arg49, Thr48, Gly344, Tyr317, Lys348, Arg52, His269, Tyr254, Met245, and Arg52.

14. The device of claim 7 , wherein the staring enzyme is bilirubin oxidase and the mutation modifies an active site of the bilirubin oxidase for oxygen reduction and electron transfer to the natural electron acceptor of bilirubin oxidase located in a trinuclear cluster of bilirubin oxidase.

15. The device of claim 14 , wherein the natural electron acceptor is dioxygen.

16. The device of claim 7 , wherein the starting enzyme is a wild-type bilirubin oxidase produced by genus Bacillus.

17. The device of claim 7 , wherein the protein coding structure is for spore coat protein gi-194015788 (ZP_03054403) from Bacillus pumilus.

18. The device of claim 10 , wherein the starting enzyme is wild-type bilirubin oxidase produced from Myrrothecium verrucaria and the mutation is at a target site of the starting enzyme selected from the group consisting of: Cys457, His456, His458, His136, His134, His96, His403, His94, His401, Asp105.

19. A device for detecting a target analyte, the device comprising:

an electron redox mediating molecule; and

a recombinant modified enzyme comprising a mutation of a protein coding sequence for a starting enzyme,

wherein the mutation is engineered to modify an active site of the starting enzyme for oxygen reduction and electron transfer to a natural electron acceptor of the starting enzyme permitting transfer of electrons to the electron redox mediating molecule, and the recombinant modified enzyme maintains enzymatic activity against the target analyte.

20. An electrochemical biosensor, comprising:

a silver/silver chloride electrode connected to one end of a circuit;

a conductive metal surface connected to another end of a circuit; and

an immobilized enzyme layer comprising:

an electron mediator molecule; and

a recombinant modified enzyme lacking an ability to transfer electrons to a natural electron acceptor and instead transfers electrons to the electron mediator molecule such that the biosensor performs in a presence of oxygen.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 19, 2014
From: MARTIN, GLENN; COLLIER, G. BRUCE; WANG, DAN
To: ABBOTT POINT OF CARE INC.
Reel/Frame 032920/0619 →
Continuity (2)
Provisional Application 61787408 · Mar 15, 2013
Related Publication 20140262776A1 · Sep 18, 2014